Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 286

1.

CRFR1 activation protects against cytokine-induced β-cell death.

Blaabjerg L, Christensen GL, Matsumoto M, van der Meulen T, Huising MO, Billestrup N, Vale WW.

J Mol Endocrinol. 2014 Dec;53(3):417-27. doi: 10.1530/JME-14-0056. Epub 2014 Oct 16.

2.

Corticotropin-releasing factor-binding protein (CRF-BP) inhibits CRF- and urotensin-I-mediated activation of CRF receptor-1 and -2 in common carp.

Manuel R, Metz JR, Flik G, Vale WW, Huising MO.

Gen Comp Endocrinol. 2014 Jun 1;202:69-75. doi: 10.1016/j.ygcen.2014.04.010. Epub 2014 Apr 24.

PMID:
24769042
3.

Expression and functional characterization of membrane-integrated mammalian corticotropin releasing factor receptors 1 and 2 in Escherichia coli.

Jappelli R, Perrin MH, Lewis KA, Vaughan JM, Tzitzilonis C, Rivier JE, Vale WW, Riek R.

PLoS One. 2014 Jan 17;9(1):e84013. doi: 10.1371/journal.pone.0084013. eCollection 2014.

4.

CRF type 2 receptors mediate the metabolic effects of ghrelin in C2C12 cells.

Gershon E, Vale WW.

Obesity (Silver Spring). 2014 Feb;22(2):380-9. doi: 10.1002/oby.20535. Epub 2013 Sep 10.

5.

Control of voltage-gated potassium channel Kv2.2 expression by pyruvate-isocitrate cycling regulates glucose-stimulated insulin secretion.

Jensen MV, Haldeman JM, Zhang H, Lu D, Huising MO, Vale WW, Hohmeier HE, Rosenberg P, Newgard CB.

J Biol Chem. 2013 Aug 9;288(32):23128-40. doi: 10.1074/jbc.M113.491654. Epub 2013 Jun 20.

6.

Posttranslational processing of human and mouse urocortin 2: characterization and bioactivity of gene products.

Vaughan JM, Donaldson CJ, Fischer WH, Perrin MH, Rivier JE, Sawchenko PE, Vale WW.

Endocrinology. 2013 Apr;154(4):1553-64. doi: 10.1210/en.2012-2011. Epub 2013 Mar 14.

7.

Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala.

Flandreau EI, Bourke CH, Ressler KJ, Vale WW, Nemeroff CB, Owens MJ.

Psychoneuroendocrinology. 2013 Aug;38(8):1349-61. doi: 10.1016/j.psyneuen.2012.11.020. Epub 2012 Dec 23.

8.

Urocortin 3 marks mature human primary and embryonic stem cell-derived pancreatic alpha and beta cells.

van der Meulen T, Xie R, Kelly OG, Vale WW, Sander M, Huising MO.

PLoS One. 2012;7(12):e52181. doi: 10.1371/journal.pone.0052181. Epub 2012 Dec 14.

9.

Chronic activation of corticotropin-releasing factor type 2 receptors reveals a key role for 5-HT1A receptor responsiveness in mediating behavioral and serotonergic responses to stressful challenge.

Neufeld-Cohen A, Kelly PA, Paul ED, Carter RN, Skinner E, Olverman HJ, Vaughan JM, Issler O, Kuperman Y, Lowry CA, Vale WW, Seckl JR, Chen A, Jamieson PM.

Biol Psychiatry. 2012 Sep 15;72(6):437-47. doi: 10.1016/j.biopsych.2012.05.005. Epub 2012 Jun 15.

10.

Cell-type specific modulation of pituitary cells by activin, inhibin and follistatin.

Bilezikjian LM, Justice NJ, Blackler AN, Wiater E, Vale WW.

Mol Cell Endocrinol. 2012 Aug 15;359(1-2):43-52. doi: 10.1016/j.mce.2012.01.025. Epub 2012 Feb 4. Review.

11.

The Local Control of the Pituitary by Activin Signaling and Modulation.

Bilezikjian LM, Vale WW.

Open Neuroendocrinol J. 2011 Jan 1;4:90-101.

12.

Photo-cross-linkers incorporated into G-protein-coupled receptors in mammalian cells: a ligand comparison.

Coin I, Perrin MH, Vale WW, Wang L.

Angew Chem Int Ed Engl. 2011 Aug 22;50(35):8077-81. doi: 10.1002/anie.201102646. Epub 2011 Jul 12.

13.

Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet.

Jamieson PM, Cleasby ME, Kuperman Y, Morton NM, Kelly PA, Brownstein DG, Mustard KJ, Vaughan JM, Carter RN, Hahn CN, Hardie DG, Seckl JR, Chen A, Vale WW.

Diabetologia. 2011 Sep;54(9):2392-403. doi: 10.1007/s00125-011-2205-6. Epub 2011 Jun 11.

14.

Systemic urocortin 2, but not urocortin 1 or stressin 1-A, suppresses feeding via CRF2 receptors without malaise and stress.

Fekete EM, Zhao Y, Szücs A, Sabino V, Cottone P, Rivier J, Vale WW, Koob GF, Zorrilla EP.

Br J Pharmacol. 2011 Dec;164(8):1959-75. doi: 10.1111/j.1476-5381.2011.01512.x.

15.

Glucocorticoids differentially regulate the expression of CRFR1 and CRFR2α in MIN6 insulinoma cells and rodent islets.

Huising MO, Pilbrow AP, Matsumoto M, van der Meulen T, Park H, Vaughan JM, Lee S, Vale WW.

Endocrinology. 2011 Jan;152(1):138-50. doi: 10.1210/en.2010-0791. Epub 2010 Nov 24.

16.

A triple urocortin knockout mouse model reveals an essential role for urocortins in stress recovery.

Neufeld-Cohen A, Tsoory MM, Evans AK, Getselter D, Gil S, Lowry CA, Vale WW, Chen A.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19020-5. doi: 10.1073/pnas.1013761107. Epub 2010 Oct 11.

17.

NMR structure of the first extracellular domain of corticotropin-releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist.

Grace CR, Perrin MH, Gulyas J, Rivier JE, Vale WW, Riek R.

J Biol Chem. 2010 Dec 3;285(49):38580-9. doi: 10.1074/jbc.M110.121897. Epub 2010 Sep 15.

18.

Expression of urocortin peptides in canine myocardium and plasma.

Veloso GF, Ohad DG, Francis AJ, Vaughan JM, Brownstein DG, Culshaw GJ, Vale WW, French AT, Jamieson PM.

Vet J. 2011 Jun;188(3):318-24. doi: 10.1016/j.tvjl.2010.05.019. Epub 2010 Jun 15.

19.

Acute effects of urocortin 2 on cardiac function and propensity for arrhythmias in an animal model of hypertension-induced left ventricular hypertrophy and heart failure.

Meili-Butz S, Bühler K, John D, Buser P, Vale WW, Peterson KL, Brink M, Dieterle T.

Eur J Heart Fail. 2010 Aug;12(8):797-804. doi: 10.1093/eurjhf/hfq054. Epub 2010 Apr 13.

20.

CRFR1 is expressed on pancreatic beta cells, promotes beta cell proliferation, and potentiates insulin secretion in a glucose-dependent manner.

Huising MO, van der Meulen T, Vaughan JM, Matsumoto M, Donaldson CJ, Park H, Billestrup N, Vale WW.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):912-7. doi: 10.1073/pnas.0913610107. Epub 2009 Dec 22.

21.

Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways.

Kelber JA, Panopoulos AD, Shani G, Booker EC, Belmonte JC, Vale WW, Gray PC.

Oncogene. 2009 Jun 18;28(24):2324-36. doi: 10.1038/onc.2009.97. Epub 2009 May 4.

22.

Social defeat stress activates medial amygdala cells that express type 2 corticotropin-releasing factor receptor mRNA.

Fekete EM, Zhao Y, Li C, Sabino V, Vale WW, Zorrilla EP.

Neuroscience. 2009 Aug 4;162(1):5-13. doi: 10.1016/j.neuroscience.2009.03.078. Epub 2009 Apr 7.

23.

Immediate and sustained blood pressure lowering by urocortin 2: a novel approach to antihypertensive therapy?

Dieterle T, Meili-Butz S, Bühler K, Morandi C, John D, Buser PT, Rivier J, Vale WW, Peterson KL, Brink M.

Hypertension. 2009 Apr;53(4):739-44. doi: 10.1161/HYPERTENSIONAHA.108.125211. Epub 2009 Feb 9.

PMID:
19204182
24.

FoxL2 and Smad3 coordinately regulate follistatin gene transcription.

Blount AL, Schmidt K, Justice NJ, Vale WW, Fischer WH, Bilezikjian LM.

J Biol Chem. 2009 Mar 20;284(12):7631-45. doi: 10.1074/jbc.M806676200. Epub 2008 Dec 23.

25.

Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation.

Hao Z, Huang Y, Cleman J, Jovin IS, Vale WW, Bale TL, Giordano FJ.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3939-44. doi: 10.1073/pnas.0712366105. Epub 2008 Feb 28.

26.

Residues of corticotropin releasing factor-binding protein (CRF-BP) that selectively abrogate binding to CRF but not to urocortin 1.

Huising MO, Vaughan JM, Shah SH, Grillot KL, Donaldson CJ, Rivier J, Flik G, Vale WW.

J Biol Chem. 2008 Apr 4;283(14):8902-12. doi: 10.1074/jbc.M709904200. Epub 2008 Jan 29.

27.

A Smad-binding element in intron 1 participates in activin-dependent regulation of the follistatin gene.

Blount AL, Vaughan JM, Vale WW, Bilezikjian LM.

J Biol Chem. 2008 Mar 14;283(11):7016-26. doi: 10.1074/jbc.M709502200. Epub 2008 Jan 8.

28.

Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal.

Kelber JA, Shani G, Booker EC, Vale WW, Gray PC.

J Biol Chem. 2008 Feb 22;283(8):4490-500. Epub 2007 Dec 18.

29.

Common and divergent structural features of a series of corticotropin releasing factor-related peptides.

Grace CR, Perrin MH, Cantle JP, Vale WW, Rivier JE, Riek R.

J Am Chem Soc. 2007 Dec 26;129(51):16102-14. Epub 2007 Dec 6.

PMID:
18052377
30.

Role of the corticotropin-releasing factor receptor type 2 in the control of food intake in mice: a meal pattern analysis.

Tabarin A, Diz-Chaves Y, Consoli D, Monsaingeon M, Bale TL, Culler MD, Datta R, Drago F, Vale WW, Koob GF, Zorrilla EP, Contarino A.

Eur J Neurosci. 2007 Oct;26(8):2303-14.

31.

Distinct structural and functional roles of conserved residues in the first extracellular domain of receptors for corticotropin-releasing factor and related G-protein-coupled receptors.

Perrin MH, Grace CR, Digruccio MR, Fischer WH, Maji SK, Cantle JP, Smith S, Manning G, Vale WW, Riek R.

J Biol Chem. 2007 Dec 28;282(52):37529-36. Epub 2007 Oct 16.

32.

Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats.

Zhao Y, Valdez GR, Fekete EM, Rivier JE, Vale WW, Rice KC, Weiss F, Zorrilla EP.

J Pharmacol Exp Ther. 2007 Dec;323(3):846-54. Epub 2007 Sep 12.

PMID:
17855476
33.

Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand.

Grace CR, Perrin MH, Gulyas J, Digruccio MR, Cantle JP, Rivier JE, Vale WW, Riek R.

Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):4858-63. Epub 2007 Mar 12.

34.

The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress.

Smith SM, Vale WW.

Dialogues Clin Neurosci. 2006;8(4):383-95. Review.

35.
36.

Cocaine withdrawal enhances long-term potentiation induced by corticotropin-releasing factor at central amygdala glutamatergic synapses via CRF, NMDA receptors and PKA.

Pollandt S, Liu J, Orozco-Cabal L, Grigoriadis DE, Vale WW, Gallagher JP, Shinnick-Gallagher P.

Eur J Neurosci. 2006 Sep;24(6):1733-43.

PMID:
17004937
38.

Pituitary actions of ligands of the TGF-beta family: activins and inhibins.

Bilezikjian LM, Blount AL, Donaldson CJ, Vale WW.

Reproduction. 2006 Aug;132(2):207-15. Review.

PMID:
16885530
39.

Structure of the ternary signaling complex of a TGF-beta superfamily member.

Allendorph GP, Vale WW, Choe S.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7643-8. Epub 2006 May 3.

40.

Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions.

Wiater E, Harrison CA, Lewis KA, Gray PC, Vale WW.

J Biol Chem. 2006 Jun 23;281(25):17011-22. Epub 2006 Apr 18.

41.

Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis.

Carlin KM, Vale WW, Bale TL.

Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3462-7. Epub 2006 Feb 21.

42.

Cocaine- and amphetamine-regulated transcript is localized in pituitary lactotropes and is regulated during lactation.

Smith SM, Vaughan JM, Donaldson CJ, Fernandez RE, Li C, Chen A, Vale WW.

Endocrinology. 2006 Mar;147(3):1213-23. Epub 2005 Dec 8.

PMID:
16339196
43.

The neurobiology of depression: inroads to treatment and new drug discovery.

Nemeroff CB, Vale WW.

J Clin Psychiatry. 2005;66 Suppl 7:5-13. Review.

44.

Antagonists of activin signaling: mechanisms and potential biological applications.

Harrison CA, Gray PC, Vale WW, Robertson DM.

Trends Endocrinol Metab. 2005 Mar;16(2):73-8. Review.

PMID:
15734148
45.

A soluble mouse brain splice variant of type 2alpha corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity.

Chen AM, Perrin MH, Digruccio MR, Vaughan JM, Brar BK, Arias CM, Lewis KA, Rivier JE, Sawchenko PE, Vale WW.

Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2620-5. Epub 2005 Feb 8.

46.

Chronic cocaine administration switches corticotropin-releasing factor2 receptor-mediated depression to facilitation of glutamatergic transmission in the lateral septum.

Liu J, Yu B, Orozco-Cabal L, Grigoriadis DE, Rivier J, Vale WW, Shinnick-Gallagher P, Gallagher JP.

J Neurosci. 2005 Jan 19;25(3):577-83.

47.

Colocalization of urocortin and neuronal nitric oxide synthase in the hypothalamus and Edinger-Westphal nucleus of the rat.

Spina MG, Langnaese K, Orlando GF, Horn TF, Rivier J, Vale WW, Wolf G, Engelmann M.

J Comp Neurol. 2004 Nov 15;479(3):271-86.

PMID:
15457505
48.

Autocrine/paracrine regulation of pituitary function by activin, inhibin and follistatin.

Bilezikjian LM, Blount AL, Leal AM, Donaldson CJ, Fischer WH, Vale WW.

Mol Cell Endocrinol. 2004 Oct 15;225(1-2):29-36. Review.

PMID:
15451565
49.
50.

NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor.

Grace CR, Perrin MH, DiGruccio MR, Miller CL, Rivier JE, Vale WW, Riek R.

Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):12836-41. Epub 2004 Aug 23.

Supplemental Content

Support Center